Actavis Plc and Allergan Inc. Chief Executive Officers Discuss Merger

David Pyott, chief executive officer Allergan Inc., left, and Brent Saunders, chief executive officer of Actavis Plc, speak after a Bloomberg Television interview in New York, U.S., on Monday, Nov. 24, 2014. Actavis Plc outspent rival Valeant Pharmaceuticals International Inc. in the $64 billion contest for Botox-maker Allergan Inc. Photographer: Scott Eells/Bloomberg via Getty Images
David Pyott, chief executive officer Allergan Inc., left, and Brent Saunders, chief executive officer of Actavis Plc, speak after a Bloomberg Television interview in New York, U.S., on Monday, Nov. 24, 2014. Actavis Plc outspent rival Valeant Pharmaceuticals International Inc. in the $64 billion contest for Botox-maker Allergan Inc. Photographer: Scott Eells/Bloomberg via Getty Images
Actavis Plc and Allergan Inc. Chief Executive Officers Discuss Merger
PURCHASE A LICENCE
How can I use this image?
AED 1,850.00
AED

DETAILS

Restrictions:
Contact your local office for all commercial or promotional uses.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Credit:
Bloomberg / Contributor
Editorial #:
459519498
Collection:
Bloomberg
Date created:
24 November, 2014
Upload date:
Licence type:
Release info:
Not released. More information
Source:
Bloomberg
Object name:
ACTAVIS ALLERGAN DEAL
Max file size:
3960 x 2640 px (33.53 x 22.35 cm) - 300 dpi - 733 KB